| Private Placement / Financing Transactions
Capstan Therapeutics: The company raised $175 million of Series B venture funding in a deal led by RA Capital Management on March 20, 2024, putting the company’s pre-money valuation at $325 million. Novartis Venture Fund, Pfizer Ventures, Leaps by Bayer, OrbiMed, Polaris Partners, Alexandria Venture Investments, Vida Ventures (Boston), Forbion, Sofinnova Investments, Johnson & Johnson Innovation – JLABS, Eli Lilly and Company Foundation, Bristol-Myers Squibb Foundation, Mubadala Capital, Perceptive Advisors and other undisclosed investors also participated in the round. The company is an operator of a biotechnology company intended to expand the therapeutic potential of in vivo RNA-based therapies through proprietary targeted delivery systems.
Engrail Therapeutics: The company raised $157 million in Series B venture funding in a deal led by F-Prime Capital, Norwest Venture Partners and Forbion on March 19, 2024, putting the company’s pre-money valuation at $93 million. Eight Roads, Longwood Fund, Pivotal Life Sciences, RiverVest Venture Partners, Red Tree Venture Capital, Ysios Capital and Abrdn also participated in the round. The company is a developer of medicines intended to target diseases that impact the nervous system.
Clasp Therapeutics: The company raised $150 million of Series A venture funding in a deal led by Catalio Capital Management, Third Rock Ventures and Novo Holdings on March 20, 2024. BrightEdge, Cure Ventures, Vivo Capital, Alexandria Venture Investments, Blackbird BioVentures and Pictet also participated in the round. The company is a developer of a cancer immunotherapeutics platform intended to help clinical-stage immuno-oncology companies to develop therapeutics.
Nouscom: The company raised EUR 67.5 million of Series C venture funding in a deal led by M Ventures, Andera Partners and Bpifrance on November 14, 2023. Versant Ventures, EQT Life Sciences, 5AM Ventures, Revelation Partners, Indaco Venture Partners, Panakes Partners, XGEN Venture, Angelini Ventures, and other undisclosed investors also participated in the round. The company is a developer of an immunotherapy platform designed to develop viral vector vaccines for the treatment of cancer.
Hippocratic AI: The company raised $55 million in Series A venture funding in a deal led by Premji Invest (US) and General Catalyst on March 18, 2024, putting the company’s pre-money valuation at $445 million. Universal Health Services, WellSpan Health, Memorial Hermann Foundation, Andreessen Horowitz, Cincinnati Children’s Hospital Medical Center, SV Angel, OhioHealth, and other undisclosed investors also participated in the round. The company’s platform aims to develop an artificial general intelligence Large Language Model (LLM) for healthcare and fitness.
Carlsmed: The company raised $52.5 million of Series C venture funding in a deal led by US Venture Partners and B Capital Group on March 18, 2024, putting the company’s pre-money valuation at $180 million. The Vertical Group and other undisclosed investors also participated in the round. The company is a developer of a spinal implant device and medical system designed to improve outcomes of spine surgery.
Profluent: The company raised $35 million of venture funding in a deal led by Spark Capital on March 21, 2024. Insight Partners, Air Street Capital, Jeff Dean and other undisclosed angel investors also participated in the round. The company is an operator of an artificial protein intended to combine real-world characterization in the wet lab with state-of-the-art generative AI models.
PocketHealth: The company raised $33 million of Series B venture funding in a deal led by Round13 Capital on March 20, 2024. Deloitte Ventures, Samsung NEXT Ventures, Radical Ventures, and Questa Capital also participated in the round. The company is a developer of a secure online platform designed to receive and share sensitive medical imaging information.
Flosonics Medical: The company raised $20 million of Series C venture funding in a deal led by New Leaf Venture on March 19, 2024. Genesys Capital, iGan Partners and Arboretum Ventures also participated in the round. The company is a developer of non-invasive hemodynamic devices.
Volta Labs: The company raised $12.7 million of Series A venture funding from Fundomo on March 22, 2024, putting the company’s pre-money valuation at $80 million. The company is an operator of a biological automation and affordable genomic sample preparation platform for genomics research.
Gliknik: The company raised $9.2 million of venture funding from undisclosed investors on March 22, 2024. The company is an operator of a biopharmaceutical business intended to treat cancer and autoimmune diseases.
Holobiome: The company raised $6.6 million of venture funding from undisclosed investors on March 19, 2024. The company is an operator of a biotechnology business focused on the human gut microbiome.
RoosterBio: The company raised $6.9 million of venture funding in the form of a combination of equity and convertible debt from BroadOak Capital Partners and other undisclosed investors on March 22, 2024. The company is an operator of a cell manufacturing technology business intended to accelerate the regenerative medicine industry.
Eisbach: The company raised $4.5 million of venture funding from Cancer Focus Fund on March 21, 2024. The company is a developer of novel medicines designed to target chromatin regulatory mechanisms.
Aignostics: The company is in the process of raising Series B venture funding on March 18, 2024. The company is a developer of an artificial intelligence-based image analysis system designed to support the discovery and validation of biomarkers.
Contrast: The company is in the process of raising venture funding on March 21, 2024. The company is a developer of an AI-powered clinical health record platform.
|
